Skip to main content
Skip to main content
IDXX logo

IDEXX Laboratories, Inc. (IDXX)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

IDXX represents IDEXX Laboratories, Inc., a Healthcare business priced at $573.29 (market cap 46B). Rated 46/100 (cautious) on growth potential, financial health, and momentum.

Last analyzed: 2026年2月7日
46/100 AI Score Target $770.00 (+34.3%) MCap 46B Vol 433K

IDEXX Laboratories, Inc. (IDXX) Healthcare & Pipeline Overview

CEOJonathan J. Mazelsky
Employees11000
HeadquartersWestbrook, ME, US
IPO Year1991

IDEXX Laboratories: A leader in companion animal diagnostics and water testing, offering innovative solutions and services to veterinary practices globally. With a strong focus on pet healthcare, IDEXX leverages its advanced technology and comprehensive product portfolio to drive growth and enhance animal well-being, commanding a significant market share.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: 2026年2月7日

Investment Thesis

IDEXX Laboratories presents a notable research candidate driven by the increasing pet ownership globally and the rising demand for advanced veterinary care. With a market cap of $51.47 billion and a profit margin of 24.6%, IDEXX demonstrates strong financial performance. The company's focus on innovation, particularly in point-of-care diagnostics and practice management software, positions it for sustained growth. Key value drivers include the expansion of its diagnostic testing services, the increasing adoption of its practice management software, and the growth in the companion animal healthcare market. The company's high P/E ratio of 48.73 reflects investor confidence in its future earnings potential. Continued investment in research and development, coupled with strategic acquisitions, will further solidify IDEXX's market leadership and drive long-term shareholder value.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market Cap of $51.47B reflects IDEXX's strong position in the animal diagnostics market.
  • P/E ratio of 48.73 indicates investor confidence in future earnings growth.
  • Profit Margin of 24.6% demonstrates efficient operations and strong pricing power.
  • Gross Margin of 61.8% highlights the value-added nature of IDEXX's products and services.
  • IDEXX operates in the growing companion animal health market, benefiting from increased pet ownership and spending on pet care.

Competitors & Peers

Strengths

  • Leading market position in companion animal diagnostics.
  • Strong brand reputation and customer loyalty.
  • Innovative product portfolio and technological capabilities.
  • Recurring revenue from consumables and subscription services.

Weaknesses

  • High P/E ratio may indicate overvaluation.
  • Dependence on the companion animal health market.
  • Exposure to regulatory risks and compliance requirements.
  • Potential for competition from emerging diagnostic technologies.

Catalysts

  • Continued growth in the companion animal health market driven by increased pet ownership and spending.
  • Expansion of IDEXX's point-of-care diagnostics and practice management software offerings.
  • Potential acquisitions of complementary businesses to expand product portfolio.
  • New product launches and technological advancements in diagnostic testing.

Risks

  • Economic downturns may reduce spending on pet care, impacting revenue growth.
  • Intense competition from established and emerging players in the veterinary diagnostics market.
  • Regulatory risks and compliance requirements in the animal health industry.
  • Product liability claims and recalls may negatively impact brand reputation and financial performance.

Growth Opportunities

  • Expansion of Point-of-Care Diagnostics: The market for point-of-care veterinary diagnostics is expanding rapidly, driven by the need for faster and more convenient diagnostic testing. IDEXX is well-positioned to capitalize on this trend with its innovative suite of in-clinic analyzers and rapid assay test kits. This market is estimated to reach $3 billion by 2028, offering IDEXX a significant opportunity to increase its market share through product innovation and strategic partnerships.
  • Growth in Veterinary Software and Services: The increasing adoption of practice management software and diagnostic imaging systems in veterinary clinics presents a significant growth opportunity for IDEXX. The company's veterinary software and services streamline clinic operations, improve efficiency, and enhance patient care. The veterinary software market is projected to reach $1.5 billion by 2027, providing IDEXX with ample room for expansion.
  • Penetration of International Markets: Expanding its presence in international markets, particularly in emerging economies, represents a key growth opportunity for IDEXX. The increasing pet ownership and rising disposable incomes in these regions are driving demand for advanced veterinary care. By tailoring its products and services to meet the specific needs of these markets, IDEXX can unlock significant growth potential. The international veterinary market is expected to grow at a CAGR of 8% over the next five years.
  • Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships can enable IDEXX to expand its product portfolio, enter new markets, and enhance its technological capabilities. By acquiring complementary businesses and forming alliances with other industry players, IDEXX can accelerate its growth and strengthen its competitive position. IDEXX has a history of successful acquisitions, and this strategy remains a key component of its growth plan.
  • Advancements in Water Quality Testing: The growing concerns about water safety and environmental regulations are driving demand for advanced water quality testing solutions. IDEXX's water quality products, including Colilert and Enterolert tests, are widely used to detect microbiological contaminants in water. The water quality testing market is projected to reach $5 billion by 2028, offering IDEXX a significant opportunity to expand its market share through product innovation and strategic partnerships.

Opportunities

  • Expansion into emerging markets with growing pet populations.
  • Development of new diagnostic tests and services for animal health.
  • Strategic acquisitions and partnerships to expand product portfolio.
  • Leveraging data analytics and artificial intelligence to improve diagnostic accuracy.

Threats

  • Intense competition from established and emerging players.
  • Economic downturns may reduce spending on pet care.
  • Changes in veterinary practice regulations and reimbursement policies.
  • Product liability claims and recalls.

Competitive Advantages

  • Strong brand reputation and customer loyalty in the veterinary diagnostics market.
  • Extensive network of veterinary reference laboratories and distribution channels.
  • Proprietary technology and intellectual property in diagnostic testing and software.
  • High switching costs for veterinary clinics due to integration of IDEXX's products and services.

About IDXX

IDEXX Laboratories, Inc., founded in 1983 and headquartered in Westbrook, Maine, has evolved into a global leader in pet healthcare innovation. The company develops, manufactures, and distributes a wide array of products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. IDEXX operates through four key segments: CAG (Companion Animal Group), Water Quality Products, LPD (Livestock, Poultry and Dairy), and Other. Its core offerings include point-of-care veterinary diagnostic products, such as instruments, consumables, and rapid assay test kits, which enable veterinarians to quickly and accurately diagnose and treat animal illnesses. The company also provides veterinary reference laboratory diagnostic and consulting services, offering advanced testing capabilities and expert support to veterinary practices. IDEXX's practice management and diagnostic imaging systems and services further enhance the efficiency and effectiveness of veterinary clinics. Additionally, IDEXX serves the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. The company's water quality products, including Colilert and Enterolert tests, are used to detect microbiological contaminants in water, ensuring public health and safety. IDEXX markets its products through a combination of direct sales, customer service, and technical support teams, as well as through independent distributors and resellers, ensuring broad market access and customer satisfaction.

What They Do

  • Develops and manufactures diagnostic products for companion animals.
  • Offers veterinary reference laboratory diagnostic and consulting services.
  • Provides practice management and diagnostic imaging systems for veterinarians.
  • Offers health monitoring and biological materials testing for biomedical research.
  • Provides diagnostic products for livestock, poultry, and dairy animals.
  • Offers products for testing water for microbiological contaminants.
  • Provides veterinary software and services for independent veterinary clinics and corporate groups.

Business Model

  • Sales of point-of-care veterinary diagnostic products, including instruments and consumables.
  • Revenue from veterinary reference laboratory diagnostic and consulting services.
  • Subscription fees for practice management software and diagnostic imaging systems.
  • Sales of water quality testing products and related services.

Industry Context

IDEXX operates within the rapidly growing veterinary diagnostics and animal health market. The industry is driven by increasing pet ownership, rising disposable incomes, and a greater emphasis on preventative care for animals. The global animal health market is projected to reach $55 billion by 2026. IDEXX competes with companies like A, ALNY, ARGX, BDX, and CAH, focusing on specialized diagnostic solutions and software. The competitive landscape is characterized by innovation and technological advancements, with companies striving to develop more accurate and efficient diagnostic tools.

Key Customers

  • Veterinary clinics and hospitals
  • Biomedical research institutions
  • Livestock, poultry, and dairy farmers
  • Water testing laboratories and municipalities
AI Confidence: 73% Updated: 2026年2月7日

Financials

Chart & Info

IDEXX Laboratories, Inc. (IDXX) stock price: $573.29 (-2.43, -0.42%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDXX.

Price Targets

Consensus target: $770.00

MoonshotScore

46/100

What does this score mean?

The MoonshotScore rates IDXX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

IDEXX Laboratories, Inc. Stock: Key Questions Answered

What are the key factors to evaluate for IDXX?

IDEXX Laboratories, Inc. (IDXX) currently holds an AI score of 46/100, indicating low score. The stock trades at a P/E of 43.8x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $770.00 (+34% from $573.29). Key strength: Leading market position in companion animal diagnostics. Primary risk to monitor: Economic downturns may reduce spending on pet care, impacting revenue growth. This is not financial advice.

How frequently does IDXX data refresh on this page?

IDXX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven IDXX's recent stock price performance?

Recent price movement in IDEXX Laboratories, Inc. (IDXX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $770.00 implies 34% upside from here. Notable catalyst: Leading market position in companion animal diagnostics. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider IDXX overvalued or undervalued right now?

Determining whether IDEXX Laboratories, Inc. (IDXX) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 43.8. Analysts target $770.00 (+34% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying IDXX?

Before investing in IDEXX Laboratories, Inc. (IDXX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding IDXX to a portfolio?

Potential reasons to consider IDEXX Laboratories, Inc. (IDXX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Leading market position in companion animal diagnostics. Additionally: Strong brand reputation and customer loyalty. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of IDXX?

Yes, most major brokerages offer fractional shares of IDEXX Laboratories, Inc. (IDXX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track IDXX's earnings and financial reports?

IDEXX Laboratories, Inc. (IDXX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for IDXX earnings announcements is recommended.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Stock data pending update may affect valuation metrics.
  • Future market conditions and competitive dynamics are subject to change.
Data Sources

Popular Stocks